Doximity Is Up 31% on a Guidance Raise-Real Bull Case Change, or AI Hype at a Premium?

The market rewarded guidance more than the quarter itself

Doximity's Q1 print was solid, not spectacular. Revenue reached $156.6 million versus $151.7 million expected, while adjusted EPS came in at $0.29, just below the $0.30 forecast. The bigger catalyst was the company's new full-year outlook of $671 million to $681 million, and the stock responded accordingly, jumping 81.46% after hours.

That move shifted the bull case. Instead of treating AI as a later-stage upside option, investors now have a stronger reason to believe adoption is already improving engagement and expanding the commercial opportunity, with management pointing to larger commercial opportunities than initially expected.

But a move of that size also raises the burden of proof. Better guidance can justify a rerating; it does not yet prove that AI revenue will arrive quickly enough to fully support the new price. That is the real tension: the market has started pricing a more optimistic AI trajectory, while the financial evidence is still catching up.

Doximity AI adoption signals looked operational

What made this quarter more credible was not just higher revenue. The adoption metrics looked embedded in actual workflow, not confined to a product announcement.

Workflow growth and usage intensity matter

Doximity reported workflow active prescriber growth exceeded 30% year over year, and management said quarterly active workflow prescribers increased more than 30% while AI use within workflows continued to deepen. That matters because tools used inside daily workflows tend to be stickier than tools clinicians only visit occasionally.

The second signal was usage intensity. Doximity said AI Search query growth of over 25% quarter-over-quarter, while other adoption measures also improved quickly, including AI prompt volume rising more than 25% sequentially and AI Scribe usage increasing tenfold year over year. Strong repeat usage is a better foundation for future monetization than a one-quarter spike in engagement.

Product quality also matters in clinical AI. Doximity said Ask was the top-performing U.S.-based model in the NOHARM benchmark. If clinicians trust the output, adoption is more likely to move from curiosity to routine use.

The commercial signal is improving, but still early

On monetization, Doximity said it has 165 health system clients now use its AI offerings and is beginning to monetize AI Search with pharmaceutical customers. That gives the bull case a clearer path from clinician engagement to enterprise revenue.

The customer base is also more substantial than many early-stage software stories. Doximity said 127 pharma and hospital customers each generated more than $500,000 in annual subscription revenue, and prior results showed 125 customers each contributed at least $500,000 in subscription-based revenue. Those cohorts also made up 83% of total revenue.

Management also reinforced the idea that AI is opening more opportunity than the company originally modeled, saying the market unlocked has been a real surprise and upside for us. That strengthens the strategic case, even if the revenue proof still needs time.

Why the skeptical case still matters

The stock may have moved ahead of the monetization proof

A useful way to frame this is simple: adoption looks real, but the income-statement proof is still early. Doximity's adjusted earnings of $0.29 a share came in just below expectations, and management said most contracted revenue is expected in fiscal third quarter. That suggests investors are betting on a near-term revenue ramp rather than waiting for fully realized AI revenue.

Higher AI spending makes margins the key watchpoint

Bulls can point to gross margins in the mid-to-high-80% range as manageable. Bears will note that this is also where timing risk shows up fastest. If AI usage keeps accelerating before monetization fully lands, the extra compute and product costs can pressure leverage.

Doximity already said non-GAAP gross margin was 89% in the prior quarter versus 91% a year earlier, mainly because of higher AI compute costs. Management has since said higher AI investment will help support long-term growth, but that also means any delay in revenue conversion would matter quickly.

Cannibalization risk has not been settled

There is also a structural question beneath the growth numbers. One analyst warned Doximity could cannibalize its own business, which is a fair caution when AI tools sit inside the same workflow as existing products. At the same time, management argues AI Search is expanding its total addressable market in healthcare.

Both views can contain some truth. The important point for investors is that the market is currently valuing the expansion case more confidently than the evidence has yet fully confirmed.

What would confirm the bullish case after earnings

The next call is straightforward: watch whether the next few quarters validate monetization after the sharp after-hours rerating.

Signals that would support the bulls

• Management's comment that most contracted revenue is expected in fiscal third quarter shows up in recognized revenue, not just pipeline.
• Adoption keeps running: AI prompt volume increased more than 25% sequentially and AI Scribe usage rose tenfold year over year continue to hold up. -Margins remain in the mid-to-high-80% range even as AI spending stays elevated.

Signals that would challenge the rally

• Revenue ramps later than expected, leaving the stock priced for a story that has not fully landed.
• Margins soften again while AI investment stays high.
• Critics are proved right that Doximity could cannibalize its own business rather than cleanly expand it.

My view: stay constructive, but do not chase on faith. If Q3 monetization shows up and margins hold, DOCS can keep proving this is more than a sentiment spike. Until then, it looks more like a credible AI adoption story than a fully confirmed monetization story.